<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): April 24, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>HEARTWARE INTERNATIONAL, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>001-34256</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>26-3636023</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>205 Newbury Street, Suite 101<BR>Framingham, MA<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>01701</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>508.739.0950</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7.01 Regulation&nbsp;FD Disclosure</B>


<P align="left" style="font-size: 10pt">HeartWare International, Inc. (NASDAQ: HTWR &#151; ASX: HIN) today announced updated results for its international clinical
trial of the HeartWare<SUP style="font-size: 85%; vertical-align: text-top">&#174;</sup> Left Ventricular Assist System. The results were presented by Dr.&nbsp;Martin Strueber,
cardiothoracic surgeon at Hannover Medical School, at the annual meeting of the International Society for Heart and
Lung Transplantation (ISHLT)&nbsp;held in Paris this week.


<P align="left" style="font-size: 10pt">The data presented at ISHLT includes all 50 patients enrolled in the trial across 5 participating centers. The data
show a survival rate of 90% at 6&nbsp;months and a survival rate of approximately 86% at 12&nbsp;months post implant*. On
average, the patients were supported by the HeartWare<SUP style="font-size: 85%; vertical-align: text-top">&#174;</sup> System for 300&nbsp;days each. The cumulative duration of
support across the group exceeded 41&nbsp;years. The patients&#146; quality of life showed significant improvement at all points
post-implant and the rates of adverse events were relatively low despite the unusually long average duration of pump
support across the patient group.


<P align="left" style="font-size: 10pt">*&nbsp;The data includes all patients through February&nbsp;26, 2009. As of today, 3 patients have yet to pass the endpoint of
the international clinical trial and the last of these is expected to do so in early June.


<P align="left" style="font-size: 10pt">A copy of the Australian Securities Exchange Announcement and full presentation is attached as an exhibit.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>


<P align="left" style="font-size: 10pt">Exhibit&nbsp;99.1 HeartWare International, Inc. ASX announcement, dated April&nbsp;24, 2009


<P align="left" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.


<P align="left" style="font-size: 10pt">HeartWare International, Inc.


<P align="left" style="font-size: 10pt">Date: April&nbsp;24, 2009



<P align="left" style="margin-left:46%; font-size: 10pt; margin-top: -11pt">By: <U><B>/</B>s/ David McIntyre&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<BR>
Name: David McIntyre
<BR>
Title: Chief Financial Officer and
<BR>
Chief Operating Officer


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c84292e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 7156}]
{"company-data": {"conformed-name": "HeartWare International, Inc.", "cik": "0001389072", "assigned-sic": "3841", "irs-number": "980498958", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-34256", "film-number": "09769481"}, "business-address": {"street1": "14000 NW 57TH COURT", "city": "MIAMI LAKES", "state": "FL", "zip": "33014", "phone": "508-739-0841"}, "mail-address": {"street1": "205 NEWBURY STREET", "street2": "SUITE 101", "city": "FRAMINGHAM", "state": "MA", "zip": "01701"}, "former-company": {"former-conformed-name": "HeartWare LTD", "date-changed": "20070206"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2009
HEARTWARE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-34256
26-3636023
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
205 Newbury Street, Suite 101
Framingham, MA
01701
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
508.739.0950
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
HeartWare International, Inc. (NASDAQ: HTWR — ASX: HIN) today announced updated results for its international clinical
trial of the HeartWare
®
Left Ventricular Assist System. The results were presented by Dr. Martin Strueber,
cardiothoracic surgeon at Hannover Medical School, at the annual meeting of the International Society for Heart and
Lung Transplantation (ISHLT) held in Paris this week.
The data presented at ISHLT includes all 50 patients enrolled in the trial across 5 participating centers. The data
show a survival rate of 90% at 6 months and a survival rate of approximately 86% at 12 months post implant*. On
average, the patients were supported by the HeartWare
®
System for 300 days each. The cumulative duration of
support across the group exceeded 41 years. The patients' quality of life showed significant improvement at all points
post-implant and the rates of adverse events were relatively low despite the unusually long average duration of pump
support across the patient group.
* The data includes all patients through February 26, 2009. As of today, 3 patients have yet to pass the endpoint of
the international clinical trial and the last of these is expected to do so in early June.
A copy of the Australian Securities Exchange Announcement and full presentation is attached as an exhibit.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 HeartWare International, Inc. ASX announcement, dated April 24, 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
HeartWare International, Inc.
Date: April 24, 2009
By:
/
s/ David McIntyre
Name: David McIntyre
Title: Chief Financial Officer and
Chief Operating Officer